Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01381692 · OUTCOME

Phase II: Minor Response Rate

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma · Source last updated 2021-10-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Assessed at cycle 6

What was measured

Response is evaluated based on Recommended Response Criteria for Waldenstrom's Macroglobulinemia (WM). Minor response is defined as achieving minor response (MR) or better (including complete response \[CR\], near CR (nCR), very good partial remission \[VGPR\], partial response \[PR\] and MR). CR: Disappearance of monoclonal protein by immmunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly, or signs or symptoms attributable to WM nCR: As CR except that immunofixation is still positive VGPR: At least 90% reduction of serum monoclonal protein using serum protein electrophoresis PR: At least 50% reduction of serum monoclonal concentration on protein electrophoresis and at least a decrease in adenopathy/organomegaly (confirmed by original mode of imaging). No new signs or symptoms of active disease. MR: At least 25% but less than 50% reduction of serum monoclonal protein and no new signs or symptoms of active disease.

Analysis population: No patients were enrolled in the phase II part of this study.

Groups in this outcome

Arm E (Phase II: Rituximab, Bortezomib, Dexamethasone)

Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Arm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)

Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm E. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm E (Phase II: Rituximab, Bortezomib, Dexamethasone)0
Arm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Response is evaluated based on Recommended Response Criteria for Waldenstrom's Macroglobulinemia (WM). Minor response is defined as achieving minor response (MR) or better (including complete response \[CR\], near CR (nCR), very good partial remission \[VGPR\], partial response \[PR\] and MR). CR: Disappearance of monoclonal protein by immmunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly, or signs or symptoms attributable to WM nCR: As CR except that immunofixation is still positive VGPR: At least 90% reduction of serum monoclonal protein using serum protein electrophoresis PR: At least 50% reduction of serum monoclonal concentration on protein electrophoresis and at least a decrease in adenopathy/organomegaly (confirmed by original mode of imaging). No new signs or symptoms of active disease. MR: At least 25% but less than 50% reduction of serum monoclonal protein and no new signs or symptoms of active disease.
groups
  1. description
    Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Arm E (Phase II: Rituximab, Bortezomib, Dexamethasone)
  2. description
    Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm E. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Arm F (Phase II: Temsirolimus, Rituximab, Bortezomib, Dexamethasone)
population Description
No patients were enrolled in the phase II part of this study.
reporting Status
POSTED
time Frame
Assessed at cycle 6
title
Phase II: Minor Response Rate
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice